Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study-Reference-Cited by-同舟云学术

Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study

Published:2024-07 Issue: Volume: Page:1-9
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Takizawa Jun¹,Teshima Takanori²,Ennishi Daisuke³,Ichikawa Satoshi⁴,Suzuki Ritsuro⁵,Kojima Akira⁶,Takahashi Yusuke⁷,Hayashi Nobuya⁷,Kawasumi Hisashi⁶,Murayama Kosho⁷,Cheung Patricia⁸,Kawata Toshio⁷,Izutsu Koji⁹

Affiliation:

1. Department of Hematology, Endocrinology and Metabolism, Niigata University Faculty of Medicine, Niigata, Japan

2. Department of Hematology, Hokkaido University Hospital, Sapporo, Japan

3. Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan

4. Department of Hematology, Tohoku University Hospital, Sendai, Japan

5. Department of Hematology and Oncology, Faculty of Medicine, Shimane University, Izumo, Japan

6. AstraZeneca K.K., Tokyo, Japan

7. AstraZeneca K.K., Osaka, Japan

8. AstraZeneca, South San Francisco, CA, USA

9. Department of Hematology, National Cancer Center Hospital, Tokyo, Japan

Funder

AstraZeneca

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2024.2370436

Reference14 articles.

1. Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies

2. Cancer stat facts. NHL—chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Bethesda (MD): National Cancer Institute; 2023. 26 September. Available from: https://seer.cancer.gov/statfacts/html/cllsll.html.

3. Differences in incidence and trends of haematological malignancies in J apan and the U nited S tates

4. Characteristics of chronic lymphocytic leukemia in Japan: Comprehensive analysis of the CLLRSG-01 study

5. Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial